Rhabdomyosarcoma (RMS) of the urinary bladder in adults and elderly is an exceptionally rare neoplasm that displays poorly differentiated solid (alveolar-like) small cell pattern, frequently indistinguishable from small cell neuroendocrine carcinoma (SCNEC). However, the histogenesis of RMS and SCNEC and their inter-relationship have not been well studied and remained controversial. We herein analyzed 23 SCNEC and 3 small round cell RMS of the bladder for neuroendocrine (synaptophysin + chromogranin A) and myogenic (desmin + myogenin) marker expression and for TERT promoter mutations. In addition, the RMS cohort and one SCNEC that was revised to RMS were tested for gene fusions using targeted RNA sequencing (TruSight Illumina Panel which includes FOXO1 and most of RMS-related other genes). Overall, significant expression of myogenin and desmin was observed in one of 23 original SCNEC justifying a revised diagnosis to RMS. On the other hand, diffuse expression of synaptophysin was noted in 2 of the 4 RMS, but chromogranin A was not expressed in 3 RMS tested. TERT promoter mutations were detected in 15 of 22 (68%) SCNEC and in two of three (67%) assessable RMS cases, respectively. None of the four RMS cases had gene fusions. Our data highlights phenotypic and genetic overlap between SCNEC and RMS of the urinary bladder. High frequency of TERT promoter mutations in SCNEC is in line with their presumable urothelial origin. In addition, the presence of TERT promoter mutation in 2 of 3 RMS and lack of FOXO1 and other gene fusions in all 4 RMSs suggest a mucosal (urothelial) origin, probably representing extensive monomorphic rhabdomyoblastic transdifferentiation in SCNEC.

Comprehensive Cancer Center Erlangen EMN Erlangen Germany

Department of Pathology and Neuropathology University Hospital and Comprehensive Cancer Center Tubingen Tubingen Germany

Department of Pathology Charles University Medical Faculty and Charles University Hospital Plzen Plzen Czech Republic

Institute of Pathology Friedrich Alexander University Erlangen Nürnberg Erlangen Germany

Zobrazit více v PubMed

Malats N, Real FX (2015) Epidemiology of bladder cancer. Hematol Oncol Clin North Am 29(2):177–89 (vii) PubMed

Lopez-Beltran A, Cheng L (2006) Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum Pathol 37(11):1371–1388 PubMed

Kouba EJ, Cheng L (2017) Understanding the genetic landscape of small cell carcinoma of the urinary bladder and implications for diagnosis, prognosis, and treatment: a review. JAMA Oncol 3(11):1570–1578 PubMed

Wang Y et al (2019) Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up. Med Oncol 36(12):98 PubMed

Ismaili N (2011) A rare bladder cancer–small cell carcinoma: review and update. Orphanet J Rare Dis 6:75 PubMed PMC

Eusebi V et al (2000) Small cell neuroendocrine carcinoma with skeletal muscle differentiation: report of three cases. Am J Surg Pathol 24(2):223–230 PubMed

Paner GP et al (2008) Rhabdomyosarcoma of the urinary bladder in adults: predilection for alveolar morphology with anaplasia and significant morphologic overlap with small cell carcinoma. Am J Surg Pathol 32(7):1022–1028 PubMed

Kieran K, Shnorhavorian M (2016) Current standards of care in bladder and prostate rhabdomyosarcoma. Urol Oncol 34(2):93–102 PubMed

Netto GJ, Amin MB, Berney DM et al (2022) The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-part B: prostate and urinary tract tumors. Eur Urol 82(5):469–482. 10.1016/j.eururo.2022.07.002 PubMed

Hurst CD, Platt FM, Knowles MA (2014) Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol 65(2):367–369 PubMed

Robinson JT et al (2011) Integrative genomics viewer. Nat Biotechnol 29(1):24–26 PubMed PMC

Bahrami A et al (2008) Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall. Mod Pathol 21(7):795–806 PubMed

Erlenbach-Wunsch K et al (2014) Expression of the LIM homeobox domain transcription factor ISL1 (Islet-1) is frequent in rhabdomyosarcoma but very limited in other soft tissue sarcoma types. Pathology 46(4):289–295 PubMed

Thompson LDR et al (2018) Sinonasal tract alveolar rhabdomyosarcoma in adults: a clinicopathologic and immunophenotypic study of fifty-two cases with emphasis on epithelial immunoreactivity. Head Neck Pathol 12(2):181–192 PubMed PMC

Cheng L et al (2004) Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer 101(5):957–962 PubMed

Ahsaini M et al (2018) A rare pure embryonal rhabdomyosarcoma of the urinary bladder in an adult successfully managed with neoadjuvant chemotherapy and surgery: a case report. J Med Case Rep 12(1):329 PubMed PMC

Allory Y et al (2014) Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 65(2):360–366 PubMed

Hoffman-Censits J et al (2021) Urothelial Cancers with small cell variant histology have confirmed high tumor mutational burden, frequent TP53 and RB mutations, and a unique gene expression profile. Eur Urol Oncol 4:297–300 PubMed

Priemer DS et al (2018) Small-cell carcinomas of the urinary bladder and prostate: TERT promoter mutation status differentiates sites of malignancy and provides evidence of common clonality between small-cell carcinoma of the urinary bladder and urothelial carcinoma. Eur Urol Focus 4(6):880–888 PubMed

Siraj AK et al (2020) Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population. Genomics 112(2):1746–1753 PubMed

Gupta S et al (2019) A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma. Hum Pathol 88:48–59 PubMed PMC

Zarrabi A, Perrin D, Kavoosi M et al (2023) Rhabdomyosarcoma: current therapy, challenges, and future approaches to treatment strategies. Cancers (Basel) 15(21):5269. 10.3390/cancers15215269 PubMed PMC

Siefker-Radtke AO, Kamat AM, Grossman HB et al (2009) Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 27(16):2592–2597. 10.1200/JCO.2008.19.0256 PubMed PMC